NewLimit closed a $45 million financing round that included investment from Lilly Ventures and other new backers, advancing the company’s anti‑aging pipeline. The round positions NewLimit to accelerate preclinical and early clinical work on programs targeting aging biology. The company, co‑founded by a high‑profile entrepreneur, said proceeds will fund pipeline expansion and translational studies aimed at demonstrating therapeutic effects on age‑related pathways.